Leap therapeutics to present new data from distinguish study of dkn-01 plus tislelizumab and waking study of dkn-01 plus tecentriq® at the esmo congress

Median progression-free survival of 11.3 months in first-line gastric cancer patients treated with dkn-01 plus tislelizumab and capox, exceeding benchmarks in the overall population and in dkk1 and pd-l1 subgroups median overall survival is not mature with only 44% of patients deceased as of the data cut enrollment ongoing in the study of dkn-01 plus tecentriq® (atezolizumab) in second- or third-line oesophagogastric cancer patients, activity in dkk1-high patients consistent with prior studies with pembrolizumab or tislelizumab cambridge, mass. , sept. 4, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (gea) from the distinguish study, a phase 2a clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with tislelizumab, beigene's anti-pd-1 antibody, and chemotherapy, at the european society for medical oncology (esmo) congress 2022 being held on september 9-12.
LPTX Ratings Summary
LPTX Quant Ranking